| (Values in U.S. Thousands) | Dec, 2018 | Sep, 2018 | Jun, 2018 | Mar, 2018 | Dec, 2017 |
| Sales | 0 | 37,160 | 21,090 | 28,140 | 41,540 |
| Sales Growth | unch | +76.20% | -25.05% | -32.26% | +2.64% |
| Net Income | 0 | -11,850 | -13,510 | -18,580 | -32,420 |
| Net Income Growth | unch | +12.29% | +27.29% | +42.69% | -609.75% |
Pernix Therapeutics Holdings Inc (PTXTQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company's product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.
Fiscal Year End Date: 12/31